What do systematic reviews say?

Phosphodiesterase 5 inhibitors (PDE5i) vs placebo

• Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Phosphodiesterase 5 inhibitors (PDE5i) vs placebo

• Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 152 participants
  Low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 122 participants
  Very low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  RR 1.33 [0.34, 5.21]
  1 study · 40 participants
  Very low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to higher improvement in WHO functional class compared with placebo (high certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 8.59 [3.95, 18.72]
  4 studies · 282 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 509 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 0.26 [0.07, 1.06]
  3 studies · 492 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 387 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 310 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 303 participants
  High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with ERA (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 0.94 [0.55, 1.6]
  1 study · 244 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 36 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  OR 3.19 [0.74, 13.64]
  2 studies · 272 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 880 participants
  Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Low